[Randomized prospective study of ceftazidime versus a cefotaxime-tobramycin combination in acute leukemia in therapeutic aplasia]. / Etude prospective randomisée, de la ceftazidime versus l'association céfotaxime-tobramycine, dans les leucémies aiguës en aplasie thérapeutique.
Presse Med
; 17(37): 1960-3, 1988 Oct 26.
Article
em Fr
| MEDLINE
| ID: mdl-2973596
ABSTRACT
In a prospective study, 157 patients with prolonged aplasia (PMN less than 500/mm3 during more than 21 days), hospitalized in a protected environment unit, were randomly assigned to receive ceftazidime alone or cefotaxime + tobramycin for initial febrile episodes. Age, sex, underlying diseases, duration of neutropenia, digestive decontamination regimen, clinical and microbiological characteristics of infections were similar in the two groups. Patients were evaluated for their initial response to antibiotics (defervescence in 48 hours, maintained 7 days) and long term response (prevention of another infection during aplasia). The overall initial response to ceftazidime was 48/71 (68 per cent) and to cefotaxime + tobramycin 55/86 (64 per cent). The long term response to ceftazidime was 33/71 (46.5 per cent) and to cefotaxime + tobramycin 31/86 (36 per cent). In conclusion, ceftazidime alone was as effective as cefotaxime + tobramycin in the first line treatment of febrile episodes in neutropenic patients.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Tobramicina
/
Leucemia
/
Cefotaxima
/
Ceftazidima
/
Controle de Infecções
Tipo de estudo:
Clinical_trials
/
Observational_studies
/
Risk_factors_studies
Limite:
Adolescent
/
Adult
/
Female
/
Humans
/
Male
Idioma:
Fr
Ano de publicação:
1988
Tipo de documento:
Article